Previous Article | Next Article 
Journal of Virology, March 2001, p. 2706-2709, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2706-2709.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Macrophage Tropism of Human Immunodeficiency Virus Type 1 Facilitates In Vivo Escape from Cytotoxic T-Lymphocyte
Pressure
M.
Schutten,1
C. A.
van Baalen,1
C.
Guillon,1
R. C.
Huisman,1
P. H. M.
Boers,1
K.
Sintnicolaas,2
R. A.
Gruters,1,3 and
A. D. M. E.
Osterhaus1,*
Institute of Virology, University Hospital
Rotterdam, 3015 GE Rotterdam,1 and
Laboratory for Histocompatibility and Immunogenetics,
Bloodbank Rotterdam, 3015 CN Rotterdam,2
The Netherlands, and UMR103, CNRS bioMerieux, ENS de Lyon,
Lyon, France3
Received 10 October 2000/Accepted 8 December 2000
 |
ABSTRACT |
Early after seroconversion, macrophage-tropic human
immunodeficiency virus type 1 (HIV-1) variants are predominantly found, even when a mixture of macrophage-tropic and non-macrophage-tropic variants was transmitted. For virus contracted by sexual transmission, this is presently explained by selection at the port of entry, where
macrophages are infected and T cells are relatively rare. Here we
explore an additional mechanism to explain the selection of
macrophage-tropic variants in cases where the mucosa is bypassed during
transmission, such as blood transfusion, needle-stick accidents, or
intravenous drug abuse. With molecularly cloned primary isolates of
HIV-1 in irradiated mice that had been reconstituted with a high dose of human peripheral blood mononuclear cells, we found that a
macrophage-tropic HIV-1 clone escaped more efficiently from specific
cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. We propose that CTLs favor the selective outgrowth of
macrophage-tropic HIV-1 variants because infected macrophages are less
susceptible to CTL activity than infected T cells.
 |
INTRODUCTION |
The predominant biological phenotype
of human immunodeficiency virus type 1 (HIV-1) isolates changes during
the course of infection. Early after seroconversion, usually only
macrophage-tropic, non-syncytium-inducing (NSI) variants are
found. With progression to AIDS, HIV-1 isolates tend to lose
their capacity to infect macrophages and may gain the ability
to induce syncytia (SI) (10, 14). It has been well
documented that only macrophage-tropic viruses persist directly
after seroconversion (21), even when a mixture of variants
was transmitted (2, 8). Data obtained in the simian
immunodeficiency virus macaque model have suggested that Langerhans
cells or macrophages are the primary target cell after sexual
transmission (12). It has been proposed that these primary
target cells act as a selective barrier against variants that are not
capable of infecting them, i.e., SI variants (12, 20).
This physical barrier is not effective if HIV enters the body via other
routes, e.g., through blood transfusion, needle-stick accidents, or
intravenous drug abuse. Also, in those cases in which
macrophages are less likely to be the sole primary target cell type, the selective outgrowth of macrophage-tropic/NSI
viruses is observed (2, 12).
Therefore, it must be assumed that additional mechanisms select against
non-macrophage-tropic variants after the virus has entered the
body. HIV-1-specific cytotoxic T lymphocytes (CTLs) have been shown to
exert strong selective pressure on HIV-1 quasispecies during
seroconversion (1, 7) and are thus a likely candidate. CTL
pressure on replication of non-macrophage-tropic and
macrophage-tropic variants was analyzed in a previously
described xenograft versus host disease (GvHD) mouse model, because it
supports high-level replication of both virus types in their
characteristic target cells (6).
 |
MATERIALS AND METHODS |
Animals.
XID mice (CBA/HNOlaHsd; Harlan Nederland BV, Zeist,
The Netherlands) received total body irradiation with syngeneic bone
marrow support. Human peripheral blood mononuclear cells (PBMC) were isolated from the whole blood of HLA B14-matched seronegative individuals by Ficoll gradient. After one wash step, cells were administered intraperitoneally (i.p.) at 3 × 106 to 5 × 106 cells
per gram of mouse body weight, which results in an acute GvHD
situation within 6 to 14 days (6). After PBMC were
administered, CTLs (107 per mouse) were injected
i.p. together with 104 IU of recombinant human
interleukin-2. This was repeated every other day in accordance
with the optimal dose determined in previous studies of passively
transferred CTLs in the HuPBL-SCID mouse model (19).
One hour after reconstitution, mice were challenged with 30 50% mouse
infectious doses of the respective HIV-1 or HIV-2 isolates i.p. Six
days after grafting and infection of the human PBMC were done, the
first signs of the acute GvHD reaction were observed, after which the
mice were sacrificed. Cells from the peritoneal lavages were analyzed
for viral load using an infectious center test. To this end, the
cells were titrated in duplicate starting at 2 × 106 cells per well using fivefold dilution steps
and cultured in the presence of HIV-permissive feeder cells. The lowest
number of cells required to detect virus by reverse transcriptase assay after 7 days of culture was taken as a measure of the viral load.
Viruses.
The HIV strains selected for the present studies
were HIV-1 ACH 320.2A.1.2 (molecularly cloned, primary, SI,
non-macrophage tropic; in short, HIV-1 #1.2) and HIV-1 ACH
320.2A.2.1 (molecularly cloned, primary, NSI, macrophage
tropic; in short, HIV-1 #2.1). These closely related viruses were
isolated from participant ACH320 from the Amsterdam cohort studies
(ACH) of HIV infection and AIDS in homosexual men, as previously
described (3). As a control, HIV-2 RH2 to 5 A10
(biologically cloned, primary, NSI, macrophage-tropic; in
short, HIV-2 #RH2-5) from the Rotterdam cohort of HIV-2-infected persons (5) was used. Replication of the viruses in
CD4+ T cells has been described previously
(17). Primary sequences of the second exon of Rev, which
includes the TCC108 epitope, were determined as previously described
(16).
CTL clones.
Two CTL clones, TCC108 and TCC112, obtained via
limiting dilution from participant ACH709 from the ACH, have been
described in detail (16, 17). Both clones are
CD4
CD8+ as determined by
flow cytometry. TCC112 did not lyse autologous CD4+ T cells (TCL2H7) infected with HIV-1. TCC108
was shown to recognize HIV-1 amino acids 67 to 75 of the Rev protein
(SAEPVPLQL) in the context of HLA B14. CTL clones were
administered to the mice 7 to 10 days after in vitro stimulation. The
presence of TCC108 cells in the lavages and their functionality
were determined by flow cytometry and a chromium release assay
(15, 17). In vitro CTL assays on autologous B and T cells
have been described previously (17). In vitro CTL assays
were performed for 4 h at an effector-to-target ratio of 10 to 1 and a peptide concentration of 10 µM.
 |
RESULTS |
HIV variants replicate readily in human PBMC in GvHD mice, without
suppression by a non-HIV-specific CD8+ clone and with the
same tropism as those used in vitro.
All viruses in this study
established infection in GvHD mice in the presence of non-HIV-specific
TCC112 cells: high numbers of HIV-1- or HIV-2-infected cells were
reisolated despite the presence of TCC112 cells (Fig.
1), similar to the results from previous
studies where no CD8+ cells were added
(11). No differences in the viral load were observed for
HIV-1 variants #1.2 and #2.1 in this respect (Fig. 1A and B). Combined
CD68 immunohistochemistry and HIV RNA in situ hybridization on tissues
from GvHD mice showed that CD68+ cells did not
contain RNA from SI variant #1.2. By contrast, RNAs from NSI variants
#2.1 and #RH2-5 were easily detected in CD68+
cells (18), indicating that these viruses did replicate in macrophages in vivo in accordance with their in vitro tropism (5, 9).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
Viral load determined by an infectious center test in
HIV-1-infected (#1.2 [SI]; #2.1 [NSI]) and HIV-2-infected (#RH2-5
[NSI]) GvHD mice that had received either the non-HIV-specific
(TCC112) or the HIV-1 Rev-specific (TCC108) CD8+ CTL clone.
The lowest amount of cells required to detect virus was taken as a
measure of viral load. Each symbol represents the viral load of an
individual mouse.
|
|
Macrophage-tropic HIV-1 escapes more easily from a
Rev-specific CTL clone in vivo.
In the presence of HIV-1
Rev-specific CTL (TCC108), clear differences in the numbers of infected
cells were observed, depending on the virus used. Replication of
HIV-2 #RH2-5, which does not contain the CTL epitope, was not
suppressed by the HIV-1 Rev-specific CTLs (Fig. 1C). The
non-macrophage-tropic primary isolate HIV-1 #1.2 (SI) was
efficiently suppressed in 13 of 14 animals (Fig. 1A). By contrast, high
numbers of infected cells were found in 7 of 14 animals infected with
the macrophage-tropic primary virus HIV-1 #2.1 (NSI) (Fig. 1B).
Regardless of whether virus could be detected in these mice, the
numbers of functional TCC108 cells in the peritoneal lavages were
comparable in all animals, as determined by flow cytometry and chromium
release assays (data not shown).
HIV variants escape from specific CTL pressure by mutations in the
minimal epitope.
The HIV-1 strains that had been passaged through
these GvHD mice (Table 1) were
subsequently screened for mutations in Rev. For this purpose,
the second exon of Rev, including the minimal epitope for
TCC108, was amplified by PCR and sequenced (16). No
mutations were observed in viruses passaged through mice which had
received the non-HIV-specific TCC112 cells (Table 1). By contrast,
viruses that could be recovered from mice despite the presence of
Rev-specific TCC108 cells, all proved to have a mutation in the minimal
epitope SAEPVPLQL (Table 1), but not outside the epitope region (not
shown). These data indicate that TCC108 cells exerted selective
pressure on HIV-1 replication in an antigen-specific and MHC class
I-restricted manner.
Some of the escape mutants are no longer recognized in in vitro
assays.
Nine-mer peptides mimicking the various wild-type or
mutant Rev epitopes were tested for in vitro recognition by TCC108,
when presented on an autologous B-cell line. Peptides corresponding to
the index epitope, as found in HIV-1 #1.2nm1 and HIV-1
#2.1nm1 (wild type for the Rev epitope), were efficiently
recognized. Accordingly, virus replication was suppressed when
autologous T cells were infected with HIV-1 #1.2nm1 or HIV-1
#2.1nm1 and cultured in the presence of TCC108 (Table 1). HIV-1
#1.2rm1 and HIV-1 #2.1rm1, which could be isolated despite the
presence of TCC108 in vivo, were no longer suppressed in these in vitro
cultures. As expected, the two peptides corresponding to the TCC108
epitope from these viruses were not recognized in vitro.
Other escape mutants are still recognized in vitro, but not in GvHD
mice.
Unexpectedly, two other viruses that had escaped in vivo CTL
pressure (HIV-1 #2.1rm2 and HIV-1 #2.1rm3) were still suppressed by
TCC108 in in vitro cultures (Table 1), despite a mutation in their Rev
epitope. Accordingly, the synthetic peptides representing these mutant
epitopes were still recognized when presented on autologous B cells
(Table 1). To confirm that HIV-1 #2.1rm2 and HIV-1 #2.1rm3 were indeed
CTL escape variants in vivo, GvHD mice grafted with HLA
B14-matched human PBMC were challenged with HIV-1 #2.1rm2 and
HIV-1 #2.1rm3 in the presence of TCC108. Virus could be isolated
from all the mice, and no additional mutations were observed,
indicating that these viruses had indeed escaped from CTL pressure in
vivo (data not shown).
 |
DISCUSSION |
Here we have used the GvHD mouse model to study interactions
between CTLs and different HIV variants. In contrast to data obtained
in the HuPBL-SCID model (19), we found no evidence for
non-HLA-restricted suppression of HIV replication (11). As
anticipated, replication of viruses containing the wild-type Rev
epitope was suppressed by specific CTLs in an HLA-restricted manner and
virus could escape from this pressure by mutation of the minimal epitope.
Thus, we defined a model system to study the interactions between CTL
and HIV-1 variants, mimicking interactions in early HIV infection.
Macrophage-tropic HIV-1 #2.1 was more efficient in escaping CTL
pressure than its closely related non-macrophage-tropic counterpart HIV-1 #1.2. Which factors, other than tropism, could have
contributed to this more successful escape from CTL pressure? Differences in the fidelity of the reverse transcriptase enzymes of
these clones are not a likely explanation, given their overall close
relatedness and similarity (4). Furthermore, the primary sequences of the CTL epitope itself and of the flanking regions are
identical for these clones (4). This excludes differences in processing and presentation of the epitope for these HIV-1 variants.
How may the macrophage tropism of transmitted viruses
contribute to escape from the immune pressure exerted by CTLs? HIV-1 #2.1 could have escaped from CTL pressure more easily if it had more
replication cycles to acquire mutations than HIV-1 #1.2, i.e., if
infected macrophages were less susceptible to CTL activity than
infected T cells. Macrophages migrate easily into peripheral tissues,
which may protect them from CTL activity, since CTLs can only affect
target cells in their immediate proximity. In addition, T cells and
macrophages differ in the expression levels of adhesion
molecules, which may also influence the CTL-target cell interaction.
Finally, the processing of antigens may differ among cells of different
lineages or depend on the activation state of cells (13).
This may also help explain the somewhat enigmatic observation that some
variants were recognized in T cells in vitro but not in PBMC in vivo.
Irrespective of the mechanism involved, CTLs appear to control
wild-type macrophage-tropic virus replication less efficiently than non-macrophage-tropic virus replication in vivo. Reduced pressure on macrophage-tropic variants allows for extra
replication cycles, enabling the virus to acquire mutations that help
it escape from CTL recognition (1) and establish chronic
infection. We therefore propose that macrophages, in addition
to acting as a barrier for non-macrophage-tropic HIV-1
variants at the port of entry (12), serve as a sanctuary
from CTL activity for macrophage-tropic variants.
 |
ACKNOWLEDGMENTS |
We acknowledge the participants of the Amsterdam Cohort Studies
on AIDS for their continuous cooperation and the donors of the
Rotterdam Blood Bank for providing HLA-typed PBMC. We thank H. Blaak, K. Wolthers, K Stittelaar, and D. J. Serdijn for critical comments and advice during the writing of this paper.
This work was supported by grant 1314 from the Dutch AIDS
Foundation. C.G. has a Marie Curie fellowship, grant ERB
BMH4-CT-98-5079.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute
of Virology, Erasmus Medical Centre Rotterdam, Dr. Molewaterplein
50, 3015 GE Rotterdam, The Netherlands. Phone: (31)-10-4088066. Fax:
(31)-10-4089485. E-mail: osterhaus{at}viro.fgg.eur.nl.
 |
REFERENCES |
| 1.
|
Borrow, P.,
H. Lewicki,
X. Wei,
M. S. Horwitz,
N. Peffer,
H. Meyers,
J. A. Nelson,
J. E. Gairin,
B. H. Hahn,
M. B. A. Oldstone, and G. M. Shaw.
1997.
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
Nat. Med.
3:205-211[CrossRef][Medline].
|
| 2.
|
Cornelissen, M.,
G. Mulder-Kampinga,
J. Veenstra,
F. Zorgdrager,
C. Kuiken,
S. Hartman,
J. Dekker,
L. Van der Hoek,
C. Sol,
R. Coutinho, and J. Goudsmit.
1995.
Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.
J. Virol.
69:1810-1818[Abstract].
|
| 3.
|
Groenink, M.,
R. A. M. Fouchier,
R. E. Y. De Goede,
F. De Wolf,
H. T. M. Cuypers,
R. A. Gruters,
H. G. Huisman, and M. Tersmette.
1991.
Phenotypic heterogeneity in a panel of infectious molecular HIV-1 clones derived from a single individual.
J. Virol.
65:1968-1975[Abstract/Free Full Text].
|
| 4.
|
Guillon, C.,
F. Bedin,
R. A. Fouchier,
H. Schuitemaker, and R. A. Gruters.
1995.
Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient.
AIDS Res. Hum. Retrovir.
11:1537-1541[Medline].
|
| 5.
|
Guillon, C.,
M. E. van der Ende,
P. H. Boers,
R. A. Gruters,
M. Schutten, and A. D. Osterhaus.
1998.
Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities.
J. Virol.
72:6260-6263[Abstract/Free Full Text].
|
| 6.
|
Huppes, W.,
B. De Geus,
C. Zurcher, and D. W. van Bekkum.
1992.
Acute human vs. mouse graft vs. host disease in normal and immunodeficient mice.
Eur. J. Immunol.
22:197-206[Medline].
|
| 7.
|
Koup, R. A.,
J. T. Safrit,
Y. Cao,
C. A. Andrews,
G. McLeod,
W. Borkowsky,
C. Farthing, and D. D. Ho.
1994.
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
J. Virol.
68:4650-4655[Abstract/Free Full Text].
|
| 8.
|
Roos, M. T.,
J. M. Lange,
R. E. de Goede,
R. A. Coutinho,
P. T. Schellekens,
F. Miedema, and M. Tersmette.
1992.
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.
J. Infect. Dis.
165:427-432[Medline].
|
| 9.
|
Schuitemaker, H.,
M. Groenink,
L. Meyaard,
N. A. Kootstra,
R. A. M. Fouchier,
R. A. Gruters,
H. G. Huisman,
M. Tersmette, and F. Miedema.
1993.
Early replication steps but not cell type-specific signalling of the viral long terminal repeat determine HIV-1 monocytotropism.
AIDS Res. Hum. Retrovir.
9:669-675[Medline].
|
| 10.
|
Schuitemaker, H.,
M. Koot,
N. A. Kootstra,
M. W. Dercksen,
R. E. Y. De Goede,
R. P. Van Steenwijk,
J. M. A. Lange,
J. K. M. Eeftink Schattenkerk,
F. Miedema, and M. Tersmette.
1992.
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations.
J. Virol.
66:1354-1360[Abstract/Free Full Text].
|
| 11.
|
Schutten, M.,
K. Tenner-Racz,
P. Racz,
D. W. van Bekkum, and A. D. Osterhaus.
1996.
Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model.
J. Gen. Virol.
77:1667-1675[Abstract/Free Full Text].
|
| 12.
|
Spira, A. I.,
P. A. Marx,
B. K. Patterson,
J. Mahoney,
R. A. Koup,
S. M. Wolinsky, and D. D. Ho.
1996.
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques.
J. Exp. Med.
183:215-225[Abstract/Free Full Text].
|
| 13.
|
Tanaka, M., and M. Kasahara.
1998.
The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28.
Immunol. Rev.
163:161-176[CrossRef][Medline].
|
| 14.
|
Tersmette, M.,
R. A. Gruters,
F. De Wolf,
R. E. Y. De Goede,
J. M. A. Lange,
P. T. A. Schellekens,
J. Goudsmit,
J. G. Huisman, and F. Miedema.
1989.
Evidence of a role for virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies with sequential HIV isolates.
J. Virol.
63:2118-2125[Abstract/Free Full Text].
|
| 15.
|
van Baalen, C. A.,
M. R. Klein,
A. M. Geretti,
I. P. M. Keet,
F. Miedema,
C. A. C. M. Van Els, and A. D. M. E. Osterhaus.
1993.
Selective in vitro expansion of HLA class I-restricted HIV-1 gag specific CD8+ T cells from seropositive individuals: identification of CTL epitopes and precursor frequencies.
AIDS
7:781-786[Medline].
|
| 16.
|
van Baalen, C. A.,
O. Pontesilli,
R. C. Huisman,
A. M. Geretti,
M. R. Klein,
F. De Wolf,
F. Miedema,
R. A. Gruters, and A. D. M. E. Osterhaus.
1997.
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
J. Gen. Virol.
78:1913-1918[Abstract].
|
| 17.
|
van Baalen, C. A.,
M. Schutten,
R. C. Huisman,
P. H. M. Boers,
R. A. Gruters, and A. D. M. E. Osterhaus.
1998.
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro.
J. Virol.
72:6851-6857[Abstract/Free Full Text].
|
| 18.
|
van der Ende, M. E.,
C. Guillon,
P. H. M. Boers,
K. Tenner-Racz,
R. A. Gruters,
A. D. M. E. Osterhaus, and M. Schutten.
1999.
Broadening of the coreceptor usage of HIV-2 strains is not correlated with increased pathogenicity in an in vivo model.
J. Gen. Virol.
81:507-513[Abstract/Free Full Text].
|
| 19.
|
van Kuyk, R.,
B. E. Torbett,
R. J. Gulizia,
S. Leath,
D. E. Mosier, and S. Koenig.
1994.
Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism.
J. Immunol.
153:4826-4833[Abstract].
|
| 20.
|
van't Wout, A. B.,
N. A. Kootstra,
G. A. Mulder-Kampinga,
N. Albrecht-van Lent,
H. J. Scherpbier,
J. Veenstra,
K. Boer,
R. A. Coutinho,
F. Miedema, and H. Schuitemaker.
1994.
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.
J. Clin. Investig.
94:2060-2067.
|
| 21.
|
Zhu, T. F.,
H. M. Mo,
N. Wang,
D. S. Nam,
Y. Z. Cao,
R. A. Koup, and D. D. Ho.
1993.
Genotypic and phenotypic characterization of HIV-1 in patients with primary infection.
Science
261:1179-1181.
|
Journal of Virology, March 2001, p. 2706-2709, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2706-2709.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Marchant, D., Neil, S. J. D., McKnight, A.
(2006). Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J. Gen. Virol.
87: 411-418
[Abstract]
[Full Text]
-
Avery, P. R., Hoover, E. A.
(2004). Gamma Interferon/Interleukin 10 Balance in Tissue Lymphocytes Correlates with Down Modulation of Mucosal Feline Immunodeficiency Virus Infection. J. Virol.
78: 4011-4019
[Abstract]
[Full Text]
-
Harouse, J. M., Buckner, C., Gettie, A., Fuller, R., Bohm, R., Blanchard, J., Cheng-Mayer, C.
(2003). CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc. Natl. Acad. Sci. USA
100: 10977-10982
[Abstract]
[Full Text]
-
Sanchez-Ramon, S., Ma Bellon, J., Resino, S., Canto-Nogues, C., Gurbindo, D., Ramos, J.-T., Munoz-Fernandez, M.
(2003). Low Blood CD8+ T-Lymphocytes and High Circulating Monocytes Are Predictors of HIV-1-Associated Progressive Encephalopathy in Children. Pediatrics
111: e168-175
[Abstract]
[Full Text]
-
Fuller, C. L., Choi, Y. K., Fallert, B. A., Capuano, S. III, Rajakumar, P., Murphey-Corb, M., Reinhart, T. A.
(2002). Restricted SIV Replication in Rhesus Macaque Lung Tissues During the Acute Phase of Infection. Am. J. Pathol.
161: 969-978
[Abstract]
[Full Text]
-
Poluektova, L. Y., Munn, D. H., Persidsky, Y., Gendelman, H. E.
(2002). Generation of Cytotoxic T Cells Against Virus-Infected Human Brain Macrophages in a Murine Model of HIV-1 Encephalitis. J. Immunol.
168: 3941-3949
[Abstract]
[Full Text]